lintuzumab
Sponsors
Memorial Sloan Kettering Cancer Center, European Organisation for Research and Treatment of Cancer - EORTC, Facet Biotech, Jonsson Comprehensive Cancer Center, Seagen Inc.
Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaLeukemiaMyelodysplastic SyndromeMyelodysplastic Syndrome (MDS)Myelodysplastic SyndromesMyeloproliferative DisordersNeutropenia
Phase 1
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
CompletedNCT00002890
Start: 1996-10-31End: 2001-01-31Target: 24Updated: 2013-06-25
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
CompletedNCT00283114
Start: 2005-11-30End: 2010-01-31Updated: 2014-12-18
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
CompletedNCT00502112
Start: 2008-03-31End: 2010-05-31Updated: 2011-10-12
Phase 2
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
CompletedNCT00016159
Start: 2000-11-30Target: 35Updated: 2013-01-16
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
NCT00006084
Start: 2001-02-28Updated: 2013-12-19
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
CompletedNCT00002800
Start: 1996-07-31End: 2003-03-31Target: 60Updated: 2013-07-03
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
WithdrawnNCT00003984
Start: 1999-02-28Updated: 2012-07-11
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
CompletedNCT00002609
Start: 1994-08-31End: 2003-02-28Updated: 2013-06-24
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
TerminatedNCT00997243
Start: 2009-11-30End: 2011-05-31Updated: 2017-05-10